美国 · 平台与数据 · MarketBeat
Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows

详细摘要
Evolus (NASDAQ:EOLS) executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027. At a company event, CEO and President David Moatazedi said Evolus has diversified beyond its flagsh
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.marketbeat.com)




